PL334348A1 - Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release - Google Patents

Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release

Info

Publication number
PL334348A1
PL334348A1 PL97334348A PL33434897A PL334348A1 PL 334348 A1 PL334348 A1 PL 334348A1 PL 97334348 A PL97334348 A PL 97334348A PL 33434897 A PL33434897 A PL 33434897A PL 334348 A1 PL334348 A1 PL 334348A1
Authority
PL
Poland
Prior art keywords
vitamin
sustained release
retarded
formulations
prolonged release
Prior art date
Application number
PL97334348A
Other languages
English (en)
Inventor
Charles W Bishop
Joyce C Knutson
Charles R Valliere
Original Assignee
Bone Care International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care International filed Critical Bone Care International
Publication of PL334348A1 publication Critical patent/PL334348A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL97334348A 1996-12-30 1997-12-10 Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release PL334348A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/775,447 US5795882A (en) 1992-06-22 1996-12-30 Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations

Publications (1)

Publication Number Publication Date
PL334348A1 true PL334348A1 (en) 2000-02-28

Family

ID=25104456

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97334348A PL334348A1 (en) 1996-12-30 1997-12-10 Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release

Country Status (15)

Country Link
US (1) US5795882A (fr)
EP (1) EP0951286B1 (fr)
JP (1) JP2001512418A (fr)
KR (1) KR20000062405A (fr)
CN (1) CN100345547C (fr)
AT (1) ATE340581T1 (fr)
AU (1) AU724153B2 (fr)
BR (1) BR9715022A (fr)
CA (1) CA2276465A1 (fr)
DE (1) DE69736745D1 (fr)
HU (1) HUP0003526A2 (fr)
MX (1) MXPA99006988A (fr)
NZ (1) NZ336511A (fr)
PL (1) PL334348A1 (fr)
WO (1) WO1998029105A2 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
JP2001511811A (ja) * 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンｄ化合物の標的治療放出
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
WO1999011272A1 (fr) * 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Formulations polymeres chargees en analogues de vitamine d3 destinees au traitement du cancer et des troubles neurodegeneratifs
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US6849616B1 (en) * 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
AU7895601A (en) * 2000-07-18 2002-01-30 Bone Care Int Inc Stabilized 1alpha-hydroxy vitamin d
WO2002039996A2 (fr) * 2000-11-16 2002-05-23 Pharmacia & Up John Company Therapie combinee contre des tumeurs comprenant du phosphate d'estramustine et des agonistes ou antagonistes de lh-rh
US20040071789A1 (en) * 2002-02-14 2004-04-15 Baron John A Calcium supplementation to reduce prostate cancer risk
US7129230B2 (en) * 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US20080260834A1 (en) * 2002-08-20 2008-10-23 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
AU2003273318A1 (en) * 2002-09-12 2004-04-30 University Of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
CA2528359A1 (fr) * 2003-06-11 2004-12-23 Novacea, Inc. Traitement du cancer au moyen de composes de vitamine d actifs associes a des agents et a des traitements radiotherapeutiques
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
CA2528378A1 (fr) * 2003-06-11 2004-12-23 Novacea, Inc. Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
WO2005011660A1 (fr) * 2003-07-29 2005-02-10 Abbott Laboratories Utilisation de vitamine d pour reguler a la baisse le systeme renine-angiotensine-aldosterone
CA2539452C (fr) * 2003-09-17 2013-10-29 Guava Technologies, Inc. Compositions et procedes pour l'analyse d'analytes cibles
CA2540325A1 (fr) * 2003-09-24 2005-04-07 Bioxell Spa Traitement du dysfonctionnement de la vessie
US7332482B2 (en) * 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
WO2005117542A2 (fr) * 2004-05-10 2005-12-15 Novacea, Inc. Traitement du cancer du pancreas a l'aide de composes a base de vitamine d active, combine a d'autres traitements
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CA2586679A1 (fr) * 2004-11-12 2006-05-18 Bioxell Spa Emploi combine de derives de vitamine d et d'agents antiproliferants pour le traitement de cancers de la vessie
CA2624897C (fr) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Procedes et articles servant a traiter l'insuffisance et la deficience en 25-hydroxyvitamine d
EP1968383B1 (fr) * 2005-12-12 2011-05-11 Women and Infants Hospital of Rhode Island Dérivés de vitamine d et leur utilisation thérapeutique
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US11752158B2 (en) * 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
US8592401B2 (en) * 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
EP2281058B1 (fr) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Procédés, compositions, utilisations, et kits utiles pour la carence en vitamine d et des troubles associés
EP2201937A1 (fr) * 2008-12-23 2010-06-30 Teva Pharmaceutical Industries Ltd. Des compositions comprenant de vitamine D ou des derivatives de vitamine D
WO2010099508A1 (fr) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
WO2011123476A1 (fr) 2010-03-29 2011-10-06 Cytochroma Inc. Procédés et compositions pour réduction de taux d'hormone parathyroïde
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103142554B (zh) * 2013-03-21 2014-11-12 青岛正大海尔制药有限公司 骨化三醇控释胶囊及其制备方法
CN103142553B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种骨化三醇缓释胶囊及其制备方法
CN103142537B (zh) * 2013-03-21 2014-11-12 青岛正大海尔制药有限公司 骨化三醇缓释剂片
CN103142555B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种阿法骨化醇缓释胶囊及其制备方法
JP6282939B2 (ja) * 2014-06-05 2018-02-21 株式会社ファンケル 耐酸性錠剤
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
KR102121400B1 (ko) * 2018-07-31 2020-06-17 (주)에이치케이바이오텍 신령버섯균사체 액체배양 추출물을 포함하는 전립선 비대증의 예방 또는 치료용 조성물
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法
IT201900003843A1 (it) * 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
CN110917163A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 一种帕立骨化醇固体口服制剂
CN110917169A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 帕立骨化醇胶囊剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2216719A (en) * 1935-07-06 1940-10-08 Hartford Nat Bank & Trust Co Vitamin
US2434015A (en) * 1942-11-21 1948-01-06 Du Pont Stable provitamin d composition
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
ATE19623T1 (de) * 1981-07-17 1986-05-15 Duphar Int Res Verfahren zur herstellung von 1-alpha-hydroxy vitamin d oder 1-alpha hydroxy previtamin d derivaten und previtamin d oder tachysteroladdukten mit geeigneten dienophilen.
JPS5910562A (ja) * 1982-07-07 1984-01-20 Teijin Ltd プレ−１α−ヒドロキシコレカルシフエロ−ル類の製造法
CH665834A5 (de) * 1983-05-09 1988-06-15 Wisconsin Alumni Res Found Verfahren zur herstellung von 1alpha,25-dihydroxyliertem vitamin d(2) und verwandten verbindungen.
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
GB2183156B (en) * 1985-03-14 1989-06-21 Chugai Pharmaceutical Co Ltd Composition for treating skin disease
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
WO1990009179A1 (fr) * 1989-02-16 1990-08-23 University Of Georgia Research Foundation, Inc. Traitement de la dyschondroplasie tibiale d'allien
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
IL110117A0 (en) * 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
ES2144239T3 (es) * 1995-06-14 2000-06-01 Schering Ag Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.

Also Published As

Publication number Publication date
NZ336511A (en) 2001-08-31
WO1998029105A3 (fr) 1998-10-15
MXPA99006988A (es) 2002-07-02
CN1251527A (zh) 2000-04-26
DE69736745D1 (de) 2006-11-09
WO1998029105A2 (fr) 1998-07-09
EP0951286B1 (fr) 2006-09-27
JP2001512418A (ja) 2001-08-21
EP0951286A2 (fr) 1999-10-27
KR20000062405A (ko) 2000-10-25
BR9715022A (pt) 2001-09-18
HUP0003526A2 (en) 2001-03-28
US5795882A (en) 1998-08-18
AU724153B2 (en) 2000-09-14
CN100345547C (zh) 2007-10-31
AU7888398A (en) 1998-07-31
ATE340581T1 (de) 2006-10-15
CA2276465A1 (fr) 1998-07-09

Similar Documents

Publication Publication Date Title
PL334348A1 (en) Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
IL153665A0 (en) Topical pharmaceutical formulations and methods of treatment
AU5876596A (en) Oral dosage and method for treating painful conditions of th e oral cavity
WO1996028148A3 (fr) Emploi d'un anti-inflammatoire non steroidien r dans une composition protectrice pour le traitement du cancer colorectal
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
GB9401891D0 (en) Therapeutic agents
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
ES2180646T3 (es) Formulaciones liquidas orales de alendronato.
WO2001030802A3 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
EP0902789A4 (fr)
EP1259240B8 (fr) Agents de traitement des troubles cutanés, tel le nicotinamide et le cADPR
BG103647A (en) Cisplatina containing microgranules
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
AU4338501A (en) Combination chemotherapy
WO2001041747A3 (fr) Preparation pharmaceutique pour traiter des affections tumorales
WO2001085188A3 (fr) Utilisation d'echinacea comme agent hematinique
GEP20043231B (en) Resorcinol Composition
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
PL355292A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction